MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP

{
  "id": "MLC-T-ONC-015378",
  "term": "MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP",
  "field": "Oncology and biomedicine",
  "definition": "An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.",
  "synonyms": [
    "Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP",
    "Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mva-tumor-specific-neoantigen-boosting-vaccine-mva-209-fsp/"
}